REC-7735 for Cancer

This trial tests a new treatment called REC-7735, a potential drug for individuals with certain types of advanced cancer that cannot be surgically removed. The trial aims to assess the drug's safety, tolerability, and its ability to slow or stop tumor growth. Participants should have solid tumors with a specific genetic mutation (PIK3CA H1047R) and have previously tried other treatments without success. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

Research has shown that another drug, REC-1245, produced by the same company as REC-7735, was well-tolerated by patients with solid tumors. In a study involving 16 patients, no serious side effects emerged that would prevent doctors from increasing the dose. Although REC-7735 remains in the early testing stages, this information about REC-1245 suggests that REC-7735 could also be safe. However, more information is needed about its safety as REC-7735 is still under development. Participants in the current trial will contribute to understanding the safety and tolerability of REC-7735 for cancer treatment.¹²³⁴⁵

Researchers are excited about REC-7735 for cancer because it introduces a new mechanism of action that targets cancer cells differently than most existing treatments. While standard treatments like chemotherapy attack both healthy and cancerous cells, REC-7735 is designed to specifically disrupt cancer cell growth, potentially reducing side effects. Additionally, REC-7735 is administered twice daily, which might allow for more consistent therapeutic levels in the body, potentially leading to better effectiveness. This novel approach has the potential to improve outcomes for patients who have not responded well to current treatment options.

Research has shown that REC-7735 has been promising in early studies. It caused tumors to shrink significantly at low doses, outperforming some approved cancer treatments. REC-7735 targets a specific change in cancer cells known as PIK3CA-H1047R, a common focus in cancer research. This treatment uses AI technology to enhance its effectiveness and safety. These early results suggest that REC-7735 could be a strong option for treating certain advanced cancers. Participants in this trial will receive REC-7735 in either the Phase 1A Dose Finding or Phase 1B Dose Expansion/Optimization arms.⁶⁷⁸⁹¹⁰